Sandbox Reserved 1627: Difference between revisions

Line 24:

===Binding interactions===

For insulin binding to induce the activation of the receptor, binding at sites 1 and 1', as well as one insulin to either binding site 2 or 2', is required <ref name= "Uchikawa" />. Although interactions at all four binding sites are highly hydrophobic, the ligand binding interactions at sites 1 and 1' are different than at sites 2 and 2'. Sites 1 and 1' are signified by interactions between <scene name='83/832953/Sites_1_and_1_prime_location/14'>PRO495, PHE497, ARG498</scene> residues from the FnIII-1 domain and particular residues on the insulin ligand. The alpha subunits also have significant <scene name='83/832953/Cysteine_bond/3'>disulfide linkages</scene> that help maintain a compact binging site. At sites 2 and 2' the FnIII-1 region has <scene name='83/832953/Sites_2_and_2_prime_location/14'>both basic residues-ARG479, LYS484, ARG488, ARG554- and hydrophobic residues- LEU486, LEU552, and PRO537-</scene> interacting with numerous residues on the surface of the insulin ligand.

For insulin binding to induce the activation of the receptor, binding at sites 1 and 1', as well as one insulin to either binding site 2 or 2', is required. <ref name= "Uchikawa" /> Although interactions at all four binding sites are highly hydrophobic, the ligand binding interactions at sites 1 and 1' are different than at sites 2 and 2'. Sites 1 and 1' are signified by interactions between <scene name='83/832953/Sites_1_and_1_prime_location/14'>PRO495, PHE497, ARG498</scene> residues from the FnIII-1 domain and particular residues on the insulin ligand. The alpha subunits also have significant <scene name='83/832953/Cysteine_bond/3'>disulfide linkages</scene> that help maintain a compact binging site. At sites 2 and 2' the FnIII-1 region has <scene name='83/832953/Sites_2_and_2_prime_location/14'>both basic residues-ARG479, LYS484, ARG488, ARG554- and hydrophobic residues- LEU486, LEU552, and PRO537-</scene> interacting with numerous residues on the surface of the insulin ligand.

At <scene name='83/832953/Sites_1_and_1_prime_location/17'>binding sites 1 and 1'</scene>, a <scene name='83/832953/Tripartite_interaction/8'>tripartite interaction</scene> occurs between three critical parts of the alpha subunits of the insulin receptor. <ref name="Uchikawa" /> The entire interface of the tripartite interaction involves many residues that are involved with intra-protomer ionic and hydrogen bonding at the binding site. The α-CT chain and the FnIII-1 domain region become in close proximity during the conformational change of the insulin receptor and their interaction involves the following residues: <scene name='83/832953/Alpha_ct_and_fniii-1/7'>ASP496, ARG498, and ASP499 on the FnIII-1 domain</scene> and the <scene name='83/832953/Alpha_ct_and_fniii-1/9'>LYS703, GLU706, and ASP707 on the α-CT domain</scene>. This duo then interacts with the L1 region, specifically ARG14, creating an ideal <scene name='83/832953/Tripartite_interaction/9'>binding site</scene> for the insulin ligand. The FnIII-1 and α-CT are interacting from the two different alpha subunits, which displays a "cross linking" scenario where the domains of the heterodimer can intertwine with each other. The tripartite interaction between the α-CT chain, FnIII-1 domain, and the L1 region is important because it allows for a strong interaction between two subunits of the insulin receptor that maintains and stabilizes the T-shape activation state for the rest of the downstream signaling to occur. <ref name="Uchikawa" />

Sandbox Reserved 1627: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 24: / Line 24: @@
 ===Binding interactions===
-For insulin binding to induce the activation of the receptor, binding at sites 1 and 1', as well as one insulin to either binding site 2 or 2', is required <ref name= "Uchikawa" />. Although interactions at all four binding sites are highly hydrophobic, the ligand binding interactions at sites 1 and 1' are different than at sites 2 and 2'. Sites 1 and 1' are signified by interactions between <scene name='83/832953/Sites_1_and_1_prime_location/14'>PRO495, PHE497, ARG498</scene> residues from the FnIII-1 domain and particular residues on the insulin ligand. The alpha subunits also have significant <scene name='83/832953/Cysteine_bond/3'>disulfide linkages</scene> that help maintain a compact binging site. At sites 2 and 2' the FnIII-1 region has <scene name='83/832953/Sites_2_and_2_prime_location/14'>both basic residues-ARG479, LYS484, ARG488, ARG554- and hydrophobic residues- LEU486, LEU552, and PRO537-</scene> interacting with numerous residues on the surface of the insulin ligand.
+For insulin binding to induce the activation of the receptor, binding at sites 1 and 1', as well as one insulin to either binding site 2 or 2', is required. <ref name= "Uchikawa" /> Although interactions at all four binding sites are highly hydrophobic, the ligand binding interactions at sites 1 and 1' are different than at sites 2 and 2'. Sites 1 and 1' are signified by interactions between <scene name='83/832953/Sites_1_and_1_prime_location/14'>PRO495, PHE497, ARG498</scene> residues from the FnIII-1 domain and particular residues on the insulin ligand. The alpha subunits also have significant <scene name='83/832953/Cysteine_bond/3'>disulfide linkages</scene> that help maintain a compact binging site. At sites 2 and 2' the FnIII-1 region has <scene name='83/832953/Sites_2_and_2_prime_location/14'>both basic residues-ARG479, LYS484, ARG488, ARG554- and hydrophobic residues- LEU486, LEU552, and PRO537-</scene> interacting with numerous residues on the surface of the insulin ligand.
 At <scene name='83/832953/Sites_1_and_1_prime_location/17'>binding sites 1 and 1'</scene>, a <scene name='83/832953/Tripartite_interaction/8'>tripartite interaction</scene> occurs between three critical parts of the alpha subunits of the insulin receptor. <ref name="Uchikawa" /> The entire interface of the tripartite interaction involves many residues that are involved with intra-protomer ionic and hydrogen bonding at the binding site. The α-CT chain and the FnIII-1 domain region become in close proximity during the conformational change of the insulin receptor and their interaction involves the following residues: <scene name='83/832953/Alpha_ct_and_fniii-1/7'>ASP496, ARG498, and ASP499 on the FnIII-1 domain</scene> and the <scene name='83/832953/Alpha_ct_and_fniii-1/9'>LYS703, GLU706, and ASP707 on the α-CT domain</scene>. This duo then interacts with the L1 region, specifically ARG14, creating an ideal <scene name='83/832953/Tripartite_interaction/9'>binding site</scene> for the insulin ligand. The FnIII-1 and α-CT are interacting from the two different alpha subunits, which displays a "cross linking" scenario where the domains of the heterodimer can intertwine with each other. The tripartite interaction between the α-CT chain, FnIII-1 domain, and the L1 region is important because it allows for a strong interaction between two subunits of the insulin receptor that maintains and stabilizes the T-shape activation state for the rest of the downstream signaling to occur. <ref name="Uchikawa" />